Search results
248 Results for 'Diagnostics'
- Technologies (25)
- Collaborations (2)
- Team (0)
- News (166)
- Pages (0)
- Multimedia (55)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 25
-
eRapid: Multiplexed Electrochemical Detection of Complex Diseases
StataDX licensed the eRapid portable electrochemical sensing technology to develop diagnostics for neurological, cardiovascular, and renal diseases with a first focus on building a point-of-care platform for difficult-to-detect neurological disorders. -
Sparkle: Instant Biosensors for Real-Time Imaging
Sparkle is revolutionizing the binder assay industry by harnessing novel chemistry to create instant fluorescent biosensors for a wide variety of uses. -
SPEAR: Ultrasensitive Protein Detection in Small Samples
Spear Bio uses a DNA nanotechnology-driven approach developed at the Wyss Institute that allows the sensitive detection of protein biomarkers in small samples using standard instruments to create new research and diagnostic assays. An ultra-sensitive assay detecting neutralizing antibodies against SARS-CoV-2 will be the first to be commercialized. -
Molecular Nucleic Acid Detection Technology to Empower Patients with Self-Testing Capabilities
This technology provides an innovative molecular diagnostic assay for high-speed, sensitive, and specific detection of nucleic acids from SARS-CoV-2 or other pathogens, performed in a newly devised reusable base unit with pathogen-specific, one-time-use consumables – first prototyped at the Wyss Institute, then transformed into an inexpensive, reliable and manufacturable detection system by 3EO Health. -
Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease Diagnostics
This nanotech-based diagnostic platform uses a unique nucleation mechanism that assembles a DNA "nanoseed" in the presence of a pathogen-derived biomarker that then is amplified within 15 minutes to create a signal for easy detection. It is highly robust, and cost-effective, and can be adapted to detect a variety of biomarkers. -
wFDCF Face Masks: A Wearable COVID-19 Diagnostic
The Problem The COVID-19 pandemic has made it starkly clear that the world lacks rapid, accurate diagnostic tests for pathogens. When patients arrive in a medical facility for treatment, the triage process is hindered by diagnostic tests that are inaccurate or take a long time to produce results. In addition, patients who are asymptomatic and...
Collaborations 2
-
Wyss DxA Industrial Participant Program
As the industry-facing component of the Wyss Diagnostics Accelerator, the Industrial Participant Program is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem that seeks to compress the timeframe for bringing new, high-impact, diagnostic technologies to market. -
Wyss Diagnostics Accelerator (DxA)
An initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs.
News 166
Multimedia 55
-
Video/AnimationWorld of OMICs w/ David Walt & Mike Snyder – BIOS RoundtableThis is a roundtable discussion on the world of OMICs with Wyss Core Faculty member David Walt and Mike Snyder of Stanford University presented by BIOS. David Walt is a Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School, a Professor of Pathology at Brigham and Women’s Hospital, a Core Faculty member at... -
Video/AnimationHow can we restore mobility to the sick and injured?Researchers at the Wyss Institute are working to improve treatment outcomes for patients suffering from reduced mobility. This video focuses on two platform technologies that could improve the quality of life for these patients: stochastic resonance and wearable soft robotics. Credit: Wyss Institute at Harvard University -
Video/AnimationHow can we get diagnostics to patients faster?The Wyss Diagnostics Accelerator (DxA) is an initiative to enable the fast creation of diagnostic technologies to solve high-value clinical problems through deep collaborations driven by unmet diagnostic needs. Credit: Wyss Institute at Harvard University -
Video/AnimationReimagine the World – Volume 2 – Diagnostics AcceleratorTwo clinicians collaborating with the Wyss Diagnostics Accelerator (DxA), Lise Johnson and Craig Hersh, as well as two members of the Wyss DxA Industrial Partnership Program, Nell Meosky Luo and Andy Levin, share how they would Reimagine the World and the personal stories that fuel their passion for the work they are doing. Credit: Wyss... -
Video/AnimationWyss Diagnostics Accelerator – The Industrial Participant ProgramThe Industrial Participant Program (IPP) is a collaboration hub between healthcare testing companies and the scientific and clinical community within the Wyss ecosystem, driven by the Wyss Diagnostics Accelerator (DxA). Members of the IPP share the common goal of fast-tracking diagnostic technologies to meet unmet, critical needs. Credit: Wyss Institute at Harvard University -
Video/AnimationReimagining Health Equity: Wyss Diagnostics AcceleratorWith the Wyss Diagnostics Accelerator (DxA), we’re reimagining health equity by accelerating the development and deployment of needed diagnostics in all settings, particularly in low-resource settings, by fostering deep collaborations driven by unmet needs. Credit: Wyss Institute at Harvard University